Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

This study uses deep learning (AI) to analyze CT scan images and predict whether a patient with esophageal cancer (squamous cell type) achieved a complete response — meaning no remaining cancer — after receiving chemotherapy combined with immunotherapy before surgery (neoadjuvant therapy). **You may be eligible if...** - You have a confirmed diagnosis of esophageal squamous cell carcinoma - You received at least one cycle of neoadjuvant chemotherapy plus immunotherapy - You had a contrast-enhanced chest CT scan before and after neoadjuvant treatment - You underwent surgery (esophagectomy) for your cancer **You may NOT be eligible if...** - You did not have pre-treatment CT imaging available - You did not undergo surgery after neoadjuvant therapy - Your imaging quality is inadequate for analysis Talk to your doctor to see if this trial is right for you.